RE: Re Nice19 Dec 2018 11:47
Oh great. So the market has put all it's eggs on this biopharma deal , which unfortunately is not to be. Very disappointing although it appears that they will be pursuing other opportunities:
"Using additional third party validatory data generated for the Company, including recent work with the Massachusetts Institute of Technology ("MIT"), the Company has already initiated discussions with other significant global suppliers of equipment for bioprocessing, where the Directors believe there is a significant market opportunity for the Company's highly differentiated point of need MS instruments. These opportunities will continue to be pursued vigorously"
Let's see if this will go lower. This is certainly one to tuck away for about 5 years now!!!